Product Overview
Compounds: A synergistic blend of BPC‑157 (15‑aa gastric peptide) and Thymosin β‑4 fragment (LKKTETQ; aa 17–23) for regenerative research.
Forms: Lyophilized powder; USA‑made purity ≥98%.
For laboratory research use only—NOT for human or veterinary use.
Batch-tested purity ≥98%. COA available—email providers@theratideusa.com.
- Tissue repair & wound healing: Both peptides are documented to accelerate soft tissue and tendon healing, enhance angiogenesis, and reduce inflammation :contentReference[oaicite:1]{index=1}.
- Thymosin β‑4 fragment activity: The 17–23 sequence (LKKTETQ) specifically stimulates angiogenesis and tissue regeneration :contentReference[oaicite:2]{index=2}.
- Enhanced oral bioavailability: TB4 fragment is orally absorbable, retains anti‑inflammatory benefits, and shows greater potency by weight :contentReference[oaicite:3]{index=3}.
- Synergistic effects: Combining BPC‑157 with Thymosin β‑4 fragment yields enhanced fibroblast migration, cell survival, and collagen support in regenerative research :contentReference[oaicite:4]{index=4}.
Findings are from pre‑clinical studies; further research is ongoing.
What's the benefit of this blend?
Designed to combine the tissue‑repair and angiogenic strengths of both peptides for enhanced recovery models.
Administration?
Reconstituted in sterile water; dosed per research protocols (e.g., IM, IV).
Oral use?
The TB4 fragment (aa 17–23) is orally bioavailable; BPC‑157 is typically administered via injection for consistent delivery.
Safety?
Highly tolerated in animal studies; no human safety data—use appropriate lab practices with PPE.
For research use only—NOT intended for human or veterinary use, or as a dietary supplement.
Safety: Lab-handling protocols and PPE required; store at ≤ –20 °C.
FDA Notice: Claims not evaluated by FDA. Not intended to diagnose, treat, cure, or prevent disease.
